Kodiak Sciences (KOD) stock was identified as In-Play by InPlay.finance on September 28, 2026, primarily due to a significant 5.10% price gap and an unusually broad trading range of 81.76% during the session. This activity was recorded alongside the company's scheduled presentation of topline results from a clinical trial, which InPlay classified as a relevant catalyst.
What Was Kodiak Sciences Announcing?
The In-Play classification for Kodiak Sciences on September 28, 2026, was contextualised by the company's news regarding its upcoming presentation of topline results. Kodiak Sciences was scheduled to present topline results from its Phase 3 GLOW Study of tarcocimab for Diabetic Macular Edema (DME) at the AAO 2026 Annual Meeting. This announcement, published on September 25, 2026, indicated an anticipated development in the company's clinical pipeline.
Diabetic Macular Edema is a serious eye condition that can lead to vision loss, affecting individuals with diabetes. Tarcocimab is Kodiak Sciences' investigational anti-VEGF therapy, designed to address this condition. The presentation of Phase 3 study results is a critical milestone for any pharmaceutical company, as it provides key data on a drug candidate's efficacy and safety, which can significantly influence its path to regulatory approval and commercialisation.
How InPlay Identified KOD as In-Play
InPlay.finance identifies stocks that are genuinely active and In-Play during the trading session by monitoring real-time market data against a set of predefined classification factors. For Kodiak Sciences (KOD) on September 28, 2026, the platform recorded its In-Play status based on several distinct observations:
- Significant Price Gap: InPlay recorded a price gap of 5.10% for KOD. This 'gap_pct' measures the percentage difference between the stock's price observed by InPlay's calculation and its previous valid trading-session close. A positive gap suggests that the stock was trading notably higher than its prior closing price.
- Wide Trading Range: The stock exhibited an exceptionally large trading range, recorded as 81.76%. This 'range_pct' indicates the percentage difference between the session's high and low prices, highlighting considerable intraday volatility. Such a wide range suggests dynamic price action throughout the trading day.
- Clinical Trial Catalyst: A 'Clinical trial' was explicitly identified as a catalyst for KOD's In-Play classification. This indicates that company-specific news related to its drug development pipeline provided significant context for the market activity observed by InPlay.
The combination of these factors—a substantial price gap, extreme intraday volatility, and a clear clinical trial catalyst—collectively contributed to Kodiak Sciences being flagged as In-Play by the InPlay.finance platform.
Kodiak Sciences' Session Performance on September 28, 2026
On September 28, 2026, Kodiak Sciences (KOD) opened the trading session at $41.94, following a previous session close of $40.84. Throughout the day, the stock experienced considerable price movement, reaching an intraday high of $42.06 and a low of $40.05. By the close of the session, KOD settled at $40.16.
Compared to its previous session's close, Kodiak Sciences' stock registered a session close change of -1.665% by the end of the day. The recorded activity reflects a dynamic trading environment, consistent with the identified In-Play factors of a significant gap and an unusually wide trading range.
Conclusion
Kodiak Sciences (KOD) was highlighted as In-Play on September 28, 2026, due to a notable 5.10% price gap and an extreme 81.76% trading range, as identified by InPlay.finance. This activity occurred as the market processed news of the company's upcoming presentation of topline results from its Phase 3 GLOW Study. InPlay's classification accurately captured the stock's pronounced movements and the underlying company developments that made it a focal point for market observers during the session.
